Clarus Ventures, a Cambridge, MA-based venture firm, has co-led a $10 million closing of Series A round of financing for biotech startup Lycera, of Ann Arbor, MI, according to the company. Lycera—which is developing chemical drugs for autoimmune diseases based on discoveries at the University of Michigan and New York University School of Medicine—says that the other firms that co-led the financing include InterWest Partners and ARCH Venture Partners. Previous backer EDF Ventures also invested in the round. Lycera expects to raise of total of $36 million in its first round of venture capital.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
